TY - JOUR
T1 - Downstream Regulatory Element Antagonist Modulator, a target for anti-thrombotic agents
AU - Cho, Jaehyung
N1 - Funding Information:
This work was supported by grants from National Institutes of Health, American Society of Hematology, and American Heart Association.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Circulating platelets participate in the process of numerous diseases including thrombosis, inflammation, and cancer. Thus, it is of great importance to understand the underlying mechanisms mediating platelet activation under disease conditions. Emerging evidence indicates that despite the lack of a nucleus, platelets possess molecules that are involved in gene transcription in nucleated cells. This review will summarize downstream regulatory element antagonist modulator (DREAM), a transcriptional repressor, and highlight recent findings suggesting its novel non-transcriptional role in hemostasis and thrombosis.
AB - Circulating platelets participate in the process of numerous diseases including thrombosis, inflammation, and cancer. Thus, it is of great importance to understand the underlying mechanisms mediating platelet activation under disease conditions. Emerging evidence indicates that despite the lack of a nucleus, platelets possess molecules that are involved in gene transcription in nucleated cells. This review will summarize downstream regulatory element antagonist modulator (DREAM), a transcriptional repressor, and highlight recent findings suggesting its novel non-transcriptional role in hemostasis and thrombosis.
KW - DREAM
KW - Platelet activation
KW - Thrombosis and hemostasis
UR - http://www.scopus.com/inward/record.url?scp=85009115802&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2017.01.002
DO - 10.1016/j.phrs.2017.01.002
M3 - Article
C2 - 28065857
AN - SCOPUS:85009115802
SN - 1043-6618
VL - 117
SP - 283
EP - 287
JO - Pharmacological Research
JF - Pharmacological Research
ER -